gemfibrozil has been researched along with metformin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Bhatia, G; Kumar, A; Maurya, RA; Sharma, S; Srivastava, AK; Srivastava, SP; Tamrakar, AK; Tripathi, VD | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Darvesh, AS; Geldenhuys, WJ; Leeper, TC; Morris, DL; Sullivan, PG; Yonutas, HM | 1 |
| Kuusi, T; Lahdenperä, S; Taskinen, MR; Tilly-Kiesi, M; Vuorinen-Markkola, H | 1 |
| Charach, G; Grosskopf, I; Weintraub, MS | 1 |
| Currier, JS | 1 |
| Arnaiz, JA; Arroyo, JA; Bianchi, L; Burgos, R; Casamitjana, R; Conget, I; de Lazzari, E; Domingo, P; Gatell, JM; Martínez, E; Milinkovic, A; Montserrat, E; Pérez-Cuevas, JB; Ribera, E; Roca, M | 1 |
| Ahmad, AT; Ajlouni, KM; Ammari, FL; Sahhar, NN | 1 |
| Awasthi, S; Nagaprashantha, L; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP | 1 |
| Alizadeh, A; Kashi, Z; Kianmehr, A; Mahrooz, A | 1 |
| Araujo, RC; Arruda, AC; Budu, A; Estrela, GR; Gregnani, MF; Neto, JCR; Perilhão, MS; Santos, WA | 1 |
| Jaikumkao, K; Lungkaphin, A; Pengrattanachot, N; Phengpol, N; Promsan, S; Sutthasupha, P; Thongnak, L | 1 |
1 review(s) available for gemfibrozil and metformin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for gemfibrozil and metformin
| Article | Year |
|---|---|
Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.
Topics: Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metformin; Middle Aged; Phospholipids; Placebos; Triglycerides | 1993 |
Effects of fibric acid derivatives and metformin on postprandial lipemia.
Topics: Bezafibrate; Chylomicrons; Gemfibrozil; Glucose Tolerance Test; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, HDL; Male; Metformin; Middle Aged; Postprandial Period | 1998 |
Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Constitution; Double-Blind Method; Female; Gemfibrozil; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Prospective Studies; Treatment Outcome | 2003 |
18 other study(ies) available for gemfibrozil and metformin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Dyslipidemias; Glycogen Phosphorylase; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Quinolines | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
Topics: Hypoglycemic Agents; Ligands; Mitochondrial Proteins; Protein Binding; Small Molecule Libraries; Thiazolidinediones | 2016 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibrozil; Growth Hormone; Guidelines as Topic; Heptanoic Acids; HIV Infections; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipodystrophy; Metabolic Diseases; Metformin; Nucleosides; Protease Inhibitors; Pyrroles; Reverse Transcriptase Inhibitors; Risk Factors; Thiazoles; Thiazolidinediones | 2000 |
Dysregulation of growth hormone in acquired generalized lipodystrophy.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemfibrozil; Glycated Hemoglobin; Human Growth Hormone; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipodystrophy; Metformin; Pituitary Function Tests | 2004 |
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.
Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Heptanoic Acids; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Metformin; Mice; Mice, Knockout; Pyrroles; Rosiglitazone; Thiazolidinediones | 2011 |
Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.
Topics: Adiponectin; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Female; Gemfibrozil; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-10; Male; Matrix Metalloproteinase 9; Metformin; Random Allocation; Rats; Rats, Wistar | 2013 |
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Topics: Adult; Atorvastatin; Biological Transport; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Female; Gemfibrozil; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged | 2016 |
PPARα-Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice.
Topics: Animals; Cell Line; Gemfibrozil; Gene Expression Regulation; Gene Knockout Techniques; Indoles; Kidney; Male; Metformin; Mice; Organic Cation Transport Proteins; Organic Cation Transporter 2; PPAR alpha; Up-Regulation | 2020 |
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Kidney Diseases; Male; Metformin; Obesity; PPAR alpha; Rats; Rats, Wistar | 2023 |